Introduction
============

Iodothyronines secreted from the thyroid gland -- in particular triiodothyronine (T3) and thyroxine (T4) -- are vital to the regulation of genes associated with cell metabolism and cell growth ([@bib1]). Hyperthyroidism and hypothyroidism are defined by an excess or deficiency of T3 and T4, respectively and can affect organ function and increase mortality ([@bib2]).

Thyroid hormone status affects the growth and homeostasis of gastrointestinal organs through binding to thyroid hormone receptors in the gastrointestinal epithelium ([@bib3]). Despite this, information on the association of hyperthyroid or hypothyroid disease with gastrointestinal cancer incidence is sparse. A cohort study of more than 7000 women revealed a higher incidence of pancreatic cancer in hyperthyroid patients compared with their euthyroid counterparts ([@bib4]). A case--control study of \~1500 patients suggested an elevated risk of liver cancer associated with hypothyroid disease ([@bib5]). Furthermore, in a case--control study of 262 individuals, more cases of hyperthyroidism were observed among esophageal cancer cases compared with their controls ([@bib6]). In addition, T4 substitution therapy has been correlated with a decreased risk of colorectal cancer ([@bib7]).

Thus, the association of hyperthyroidism and hypothyroidism diagnoses with the risk of gastrointestinal cancer has been evaluated for some, but not all, gastrointestinal cancers. We therefore conducted a population-based cohort study to examine the association between a diagnosis of hyperthyroid or hypothyroid disease and the incidence of gastrointestinal cancer overall and according to cancer site.

Subjects and methods
====================

We conducted a nationwide population-based Danish cohort study between January 1, 1978 and November 30, 2013. Individual-level data linkage of Danish medical registries was possible using the civil registration number, a unique identification number assigned to all Danish residents at birth or immigration ([@bib8]).

Study population
----------------

From the Danish National Patient Registry, we identified all patients with a hospital diagnosis of hyperthyroidism or hypothyroidism in Denmark during the study period. The Danish National Patient Registry has registered all inpatient hospital admissions since 1977 and all outpatient clinic and emergency department visits since 1995 ([@bib9]). In the Danish National Patient Registry, all diagnoses are classified according to the 8th revision of the *International Classification of Diseases* (ICD-8) until 1994 and the 10th revision (ICD-10) thereafter. The ICD codes used in this study are listed in Supplementary Table 1 (see section on [supplementary data](#supp1){ref-type="supplementary-material"} given at the end of this article). We excluded all patients born outside Denmark (*n* = 12,695) and patients diagnosed with hyperthyroidism and hypothyroidism on the same date (*n* = 537).

Data on cancers and comorbid conditions
---------------------------------------

Using the Danish Cancer Registry (DCR) we retrieved data on gastrointestinal cancer diagnoses. The DCR contains data on almost all cancer diagnoses in Denmark since 1943 ([@bib10]). We considered the following cancers: esophageal, stomach, small intestinal, colon, rectal, anal, liver, gallbladder and biliary tract and pancreatic cancer. We excluded all patients diagnosed with these cancers before the date of diagnosis of hyperthyroidism or hypothyroidism. We also grouped the cancers into groups based on common etiologies: alcohol-related (esophageal, small intestinal, colon, rectum, liver), smoking-related (esophageal, stomach, colon, rectum and pancreas), immune-related (stomach, small intestinal, anal, liver and gallbladder and biliary tract) and obesity-related (esophageal, stomach, colon, rectum, pancreas and gallbladder and biliary tract) cancers ([@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18]). When assessing the association of thyroid disease with rectal cancer risk, we ascertained information on the receipt of a colonoscopy with or without polyp removal after diagnosis of thyroid disease disregarding colonoscopies performed within 1 month before rectal cancer diagnosis. Information on colonoscopies was retrieved from the Danish National Patient Registry using the Nordic Medico-Statistical Committee Classification of Surgical Procedures (See Supplementary Table 1 for procedure codes) ([@bib19]).

To assess comorbid conditions recorded in the Danish National Patient Registry, we used the Charlson Comorbidity Index (CCI) score ([@bib20]), which is based on disease categories, each weighted according to its impact on 1-year mortality. The CCI can be used to assess the overall burden of comorbidity ([@bib21]). We defined three levels of comorbidity: no (score 0), moderate (score 1--2) and severe comorbidity (score ≥ 3). We excluded gastrointestinal cancers from the CCI score. We also calculated the prevalence of some selected comorbid conditions likely to confound our findings (alcoholism, inflammatory bowel disease, other autoimmune disease, pancreatitis, chronic obstructive pulmonary disease (COPD), diabetes, obesity, human immunodeficiency virus (HIV) and gastrointestinal bleeding).

Statistical analyses
--------------------

We followed all patients from the date of their thyroid disease diagnosis until the date of the first gastrointestinal cancer diagnosis, emigration, death or November 30, 2013, whichever occurred first. Patients with hyperthyroidism were censored if they had a subsequent diagnosis of hypothyroidism and vice versa. We calculated standardized incidence ratios (SIRs) as a measure of the relative risk, comparing the observed number of cancers among patients with hyperthyroidism or hypothyroidism with the expected number. The expected number of cancers was estimated based on national cancer incidence rates by age (1-year age groups), sex and calendar year (1-year intervals) multiplied by the time of follow-up observed in our cohort. We computed corresponding 95% CIs for the SIRs assuming that the observed number of cases in a specific category followed a Poisson distribution. Exact 95% CIs were used when the observed number was less than ten; otherwise Byar's approximation was used ([@bib22]). We performed analyses for each type of cancer stratified by duration of follow-up (\<1, 1--5, \>5 years and overall) and type of thyroid disease. We computed 10-year absolute risks of the gastrointestinal cancers of interest, treating death as a competing risk.

Ethical considerations
----------------------

This study was approved by the Danish Data Protection Agency (record number 1-16-02-1-08). No ethical approval or patient consent is needed for registry-based studies conducted in Denmark.

Results
=======

Overall patient characteristics
-------------------------------

We included 163,972 patients; 92,783 patients had hyperthyroidism and 71,189 had hypothyroidism. In both groups, the vast majority of patients were women (82.5 and 83.9% respectively). In general, patients with hypothyroidism had a higher level of comorbidity compared with hyperthyroid patients. Hypothyroid patients were more likely to have a history of obesity, COPD, autoimmune diseases and diabetes. There was an equal distribution of in- and outpatient diagnoses among both hyperthyroidism and hypothyroidism patients ([Table 1](#tbl1){ref-type="table"}). Descriptive characteristics stratified by type of hyperthyroidism are outlined in [Table 2](#tbl2){ref-type="table"}. Table 1Descriptive characteristics of 163,972 patients with hyper- or hypothyroidism diagnosed in Denmark in the period 1978--2013.Hyperthyroidism *N* = 92,783Hypothyroidism *N* = 71,189Age (years) 0--2965527.1%61478.6% 30--4921,50723.2%15,29121.5% 50--6934,49037.2%23,36032.8% 70+30,23432.6%26,39137.1%Sex Women76,56482.5%59,72183.9% Men16,21917.5%11,46816.1%Year of diagnosis 1978--198280158.6%36515.1% 1983--198768287.4%38155.4% 1988--199277288.3%50247.1% 1993--199714,18415.3%761210.7% 1998--200218,50120.0%10,76615.1% 2003--200718,45819.9%15,41321.7% 2008--201319,06920.6%24,90835.0%Patient type Inpatient43,48247.3%35,76250.2% Half-day patient38554.2%19792.8% Outpatient45,08648.6%33,44847.0%Comorbidity Alcoholism13381.4%20482.9% Autoimmune disease69707.5%886512.5% Pancreatitis5930.6%7281.0% COPD77658.4%726910.2% IBD9351.0%8471.2% Colitis ulcerosa6190.7%5530.8% Crohn's disease3380.4%2730.4% Diabetes61026.6%767110.8% Obesity30693.3%53417.5% HIV22\<0.1%20\<0.1% GI bleeding7640.8%10231.4%Charlson Comorbidity Index score Low (0)69,85275.3%46,64368.3% Medium (1--2)19,66321.2%18,67626.2% High (≥3)32683.5%38705.4%[^1] Table 2Descriptive characteristics of 92,783 patients with hyperthyroidism diagnosed in Denmark in the period 1978--2013, stratified by type of hyperthyroidism.Hyperthyroidism *N* = 92,783**Graves' disease** *N* (%)**Struma nodosa toxica** *N* (%)**Other hyperthyroidism** *N* (%)Total38,508 (100.0)34,703 (100.0)19,572 (100.0)Age (years) 0--294149 (10.8)922 (2.7)1481 (7.6) 30--4911,649 (30.3)5844 (16.8)4014 (20.5) 50--6913,120 (34.1)14,897 (42.9)6473 (33.1) 70+9590 (24.9)13,040 (37.6)7604 (38.9)Sex Women31,897 (82.8)29,166 (84.0)15,501 (79.2) Men6611 (17.2)5537 (16.0)4071 (20.8)Year of diagnosis 1978--19823082 (8.0)4932 (14.2)1 (\<0.1) 1983--19872353 (6.1)4475 (12.9)0 (0.0) 1988--19922601 (6.8)5022 (14.4)105 (0.5) 1993--19976385 (16.6)4993 (14.4)2806 (14.3) 1998--20028649 (22.5)5395 (15.6)4457 (22.8) 2003--20078975 (23.3)4765 (13.7)4718 (24.1) 2008--20136463 (16.8)5121 (14.8)7485 (38.2)Patient type Inpatient17,730 (46.0)18,240 (52.6)7872 (40.2) Half-day patient1686 (4.4)1680 (4.8)489 (2.5) Outpatient19,092 (49.6)14,783 (42.6)11,211 (57.3)Comorbidity Alcoholism583 (1.5)318 (0.9)437 (2.2) Autoimmune disease2771 (7.2)2270 (6.5)1929 (9.9) Pancreatitis214 (0.6)186 (0.5)193 (1.0) COPD2830 (7.4)2653 (7.7)2281 (11.7) IBD381 (1.0)292 (0.8)262 (1.3) Colitis ulcerosa259 (0.7)183 (0.5)177 (0.9) Crohn's disease138 (0.4)102 (0.3)98 (0.5) Diabetes2226 (5.8)2321 (6.7)1555 (8.0) Obesity1194 (3.1)965 (2.8)910 (4.7) HIV7 (\<0.1)5 (\<0.1)10 (0.1) GI bleeding273 (0.7)223 (0.6)268 (1.4)Charlson Comorbidity Index score Low (0)30,187 (78.4)26,670 (76.9)12,995 (66.4) Medium (1--2)7210 (18.7)7061 (20.3)5392 (27.6) High (≥3)1111 (2.9)972 (2.8)1185 (6.1)[^2]

Hyperthyroid patients (*n* = 92,783)
------------------------------------

Patients were followed for a median time of 7.5 years (inter-quartile range (IQR): 3.0--13.4 years). Median age at hyperthyroid diagnosis was 61.0 years (IQR: 46.5--73.7 years). In patients with hyperthyroid disease, we observed an increased risk of both overall gastrointestinal cancer (SIR: 1.17; 95% CI: 1.13--1.22) and site-specific gastrointestinal cancers except cancer of the small intestines ([Table 3](#tbl3){ref-type="table"}). Within the first year following a diagnosis of hyperthyroid disease, risk of all gastrointestinal cancers was elevated. After more than 5 years of follow-up, only pancreatic and gallbladder and biliary tract cancer risk was slightly elevated ([Table 3](#tbl3){ref-type="table"}). Results stratified by type of hyperthyroid disorder are presented in Supplementary Tables 2, 3 and 4. Overall, the absolute risk of gastrointestinal cancer was 2.4% (95% CI: 2.3--2.5%) after 10 years of follow-up. Table 3SIRs and associated 95% CIs for gastrointestinal cancers in 92,783 patients with hyperthyroidism diagnosed in Denmark in the period 1978--2013, stratified by time of follow-up.Cancer siteOverall\<1 year1--5 years\>5 years**OESIROESIROESIROESIR**Overall262822461.17 (1.13--1.22)4802082.31 (2.10--2.52)7266871.06 (0.98--1.14)142213511.05 (1.00--1.11)Esophagus1171031.14 (0.94--1.37)2592.67 (1.73--3.94)24310.77 (0.49--1.16)68621.09 (0.85--1.39)Stomach2151741.24 (1.08--1.42)45182.50 (1.83--3.35)62571.08 (0.83--1.39)108981.10 (0.90--1.33)Small intestines29281.04 (0.70--1.50)522.04 (0.66--4.75)981.09 (0.50--2.08)15170.87 (0.49--1.44)Colon112210051.12 (1.05--1.18)203912.22 (1.93--2.55)3033041.00 (0.89--1.12)6166091.01 (0.93--1.09)Rectum4844271.13 (1.04--1.24)73401.83 (1.43--2.30)1471311.12 (0.95--1.32)2642551.03 (0.91--1.17)Anal canal44371.18 (0.86--1.58)1133.50 (1.74--6.26)9110.84 (0.38--1.59)24231.03 (0.66--1.53)Liver90831.08 (0.87--1.33)1882.27 (1.34--3.59)18260.70 (0.41--1.10)54501.09 (0.82--1.42)Gallbladder and biliary tract102821.25 (1.02--1.51)1682.00 (1.14--3.25)30261.16 (0.78--1.66)56481.17 (0.88--1.51)Pancreas4253081.38 (1.25--1.52)84283.00 (2.39--3.71)124931.33 (1.11--1.59)2171871.16 (1.01--1.32)Smoking-related cancers236320161.17 (1.13--1.22)4301872.30 (2.09--2.53)6606171.07 (0.99--1.16)127312131.05 (0.99--1.11)Immune-related cancers4804041.19 (1.08--1.30)95402.40 (1.95--2.94)1281281.00 (0.84--1.19)2572371.09 (0.96--1.23)Alcohol-related cancers184216451.12 (1.07--1.17)3241512.15 (1.92--3.29)5015001.00 (0.92--1.09)10179941.02 (0.96--1.09)Obesity-related cancers246520981.18 (1.13--1.22)4461952.29 (2.08--2.51)6906431.07 (1.00--1.16)132912611.05 (1.00--1.11)[^3]

Hypothyroid patients (*n* = 71,189)
-----------------------------------

Patients were followed for a median time of 4.9 years (IQR: 1.8--9.9 years). Median age at hypothyroid diagnosis was 62.9 years (IQR: 45.9--76.1 years). Patients with hypothyroidism had an increased risk of gastrointestinal cancer overall (SIR: 1.23; 95% CI: 1.17--1.30) and increased risk of each gastrointestinal cancer except for rectal cancer ([Table 4](#tbl4){ref-type="table"}). Within the first year following a diagnosis of hypothyroid disease, risk of all gastrointestinal cancers was elevated. The risk of cancer of the stomach, anal canal, liver, gallbladder and biliary tract and immune related was increased beyond 5 years of follow-up. The risk of rectal cancer was increased within the first year after hypothyroidism diagnosis but was decreased after 5 years (SIR: 0.79; 95% CI: 0.64--0.96). In total, 11,232 patients (15.8%) underwent colonoscopy prior to their diagnosis of hypothyroidism. Patients who received a colonoscopy with polyp removal had lower risk of rectal cancer compared with the background population (SIR: 0.29; 95% CI: 0.01--1.63). In contrast, the risk of rectal cancer among patients undergoing colonoscopy without polyp removal was comparable to that in the general population (SIR: 1.09; 95% CI: 0.68--1.67). The absolute risk of gastrointestinal cancer overall was 2.4% (95% CI: 2.2--2.5) after 10 years of follow-up. Table 4SIRs and associated 95% CIs for gastrointestinal cancers in 71,189 patients with hypothyroidism diagnosed in Denmark in the period 1978--2013, stratified by time of follow-up.Cancer siteOverall\<1 year1--5 years\>5 years**OESIROESIROESIROESIR**Overall160813031.23 (1.17--1.30)5021653.04 (2.78--3.32)4494790.94 (0.85--1.03)6576591.00 (0.92--1.08)Esophagus76571.32 (1.04--1.66)2673.59 (2.35--5.27)19210.90 (0.54--1.41)31291.07 (0.73--1.51)Stomach148991.49 (1.26--1.75)43143.12 (2.26--4.21)44391.14 (0.83--1.53)61471.30 (0.99--1.66)Small intestines20161.25 (0.77--1.94)924.60 (2.11--8.75)560.86 (0.28--2.02)580.73 (0.27--1.59)Colon7315911.24 (1.15--1.33)230743.12 (2.73--3.55)2152151.00 (0.87--1.14)2863020.95 (0.84--1.06)Rectum2322430.95 (0.83--1.08)75312.41 (1.90--3.03)61900.68 (0.52--0.87)961220.79 (0.64--0.96)Anal canal30221.39 (0.94--1.99)632.36 (0.86--5.13)580.65 (0.21--1.51)19111.68 (1.01--2.63)Liver71471.50 (1.17--1.89)1963.11 (1.87--4.86)19181.08 (0.65--1.69)31241.39 (0.96--1.96)Gallbladder and biliary tract72481.49 (1.17--1.88)1963.01 (1.81--4.70)20181.11 (0.68--1.71)33241.38 (0.95--1.94)Pancreas2281791.27 (1.11--1.45)75223.36 (2.64--4.21)61650.93 (0.71--1.20)92921.00 (0.81--1.23)Smoking-related cancers141511701.21 (1.15--1.27)4491483.03 (2.76--3.33)4004300.93 (0.84--1.03)5665920.96 (0.88--1.04)Immune-related cancers3412331.47 (1.32--1.63)96313.13 (2.53--3.82)93881.06 (0.86--1.30)1521141.33 (1.13--1.56)Alcohol-related cancers11309551.18 (1.12--1.25)3591202.99 (2.69--3.32)3193500.91 (0.82--1.02)4524850.93 (0.85--1.02)Obesity-related cancers148712181.22 (1.16--1.28)4681543.03 (2.76--3.32)4204480.94 (0.85--1.03)5996160.97 (0.90--1.05)[^4]

Discussion
==========

In this cohort study of 163,972 Danish patients with a hospital-verified diagnosis of either hyperthyroidism or hypothyroidism, we found an elevated risk of most gastrointestinal cancers compared with the general population. The associations were most pronounced in the first year following hyper- or hypothyroidism diagnosis. Although the associations generally attenuated over time, an excess risk of some gastrointestinal cancers may persist more than 5 years after a diagnosis of either hyperthyroidism or hypothyroidism.

For all associations examined in the present study, gastrointestinal cancer risks were highest in the first year following a diagnosis of either hyperthyroidism or hypothyroidism. This is likely to be attributable to increased medical attention (i.e. detection bias) due to frequent contact to the healthcare system in the first period following a diagnosis of a thyroid disease. Some gastrointestinal cancers may also present with symptoms mimicking thyroid dysfunction such as fatigue, fever, gastrointestinal symptoms and weight loss. This could lead to an early cancer diagnosis, increasing the SIRs in the first year of follow-up (i.e. reverse causation).

Few studies have investigated the long-term risk of gastrointestinal cancer in patients with thyroid disease ([@bib4], [@bib5], [@bib6], [@bib7]). Our estimates of the association between hyperthyroidism and gastrointestinal cancer risk after more than 5 years of follow-up were generally distributed around the null, indicating no excess or decreased cancer risk. However, we observed slight increases in pancreatic, and gallbladder and biliary tract cancer among patients with hyperthyroidism. Similarly, Goldman *et al.* ([@bib4]) demonstrated an increased risk of pancreatic cancer in patients with hyperthyroidism, although their estimates were imprecise due to low numbers. Confounding by tobacco smoking may explain the observed increase in pancreatic cancer risk among patients with hyperthyroidism, as tobacco smoking is associated with both hyperthyroidism ([@bib23]) and pancreatic cancer ([@bib15]). Unfortunately, tobacco smoking is not recorded in the Danish National Patient Registry. Accordingly, we were unable to control for this factor. However, we saw no increase in the risk of smoking-related cancers as a group among patients with hyperthyroidism, reducing the likelihood that tobacco smoking is the sole explanation for this observed association.

Among patients with hypothyroidism, the numbers of observed and expected cancers were comparable, with the exception of cancers of the stomach, rectum and anus. Our finding of an increased risk of stomach cancer agrees with results from Goldman *et al.* ([@bib4]) who observed a higher incidence of stomach cancer in patients with Hashimoto's thyroiditis -- a subtype of hypothyroidism. As tobacco smoking is a risk factor for both stomach cancer ([@bib18]) and Hashimoto's thyroiditis, confounding by tobacco smoking could be an explanation for our finding, although we did not observe an increased risk of other smoking-related cancers among patients with hypothyroid disease. The observed increased risk of anal cancer in patients with hypothyroidism is based on low numbers of cancers and is therefore most likely attributable to chance.

In the present study, we found a slight decrease in long-term rectal cancer risk among patients with hypothyroidism. Hypothyroidism may cause gastrointestinal bleeding ([@bib24]), leading to colonoscopies, thereby decreasing rectal cancer risk via removal of rectal polyps. Accordingly, we observed a decreased risk of rectal cancer in patients undergoing colonoscopy with polyp removal but not among those without polyp removal, compared with the background population. However, our estimates of this association are imprecise.

Several issues should be considered when interpreting our findings. The population-based design of our study in a tax-financed uniform health care system ensured equal medical access for all participants and long-term, virtually complete follow-up. The prospective data collection from valid electronic registries minimizes the possibilities of underreporting of cancer diagnoses or misclassification of exposure. Nonetheless, we had no access to primary care data, and therefore, no information on subclinical thyroid disease, which is more common than clinical thyroid disease ([@bib25]). Accordingly, our observed associations may be overestimated, as any potential association between thyroid disease and gastrointestinal cancer may depend on the severity of the thyroid disease. We had no data on potential confounders such as environmental or lifestyle exposures including, among others, tobacco smoking and alcohol consumption. We also lacked information on blood levels of thyroid-stimulating hormone and thyroid hormones, as well as data on prescription drugs indicated for thyroid disease. Prompt medical treatment after the diagnosis of a thyroid disorder is likely to reverse the effect of thyroid disease, which may neutralize an association between thyroid disease and gastrointestinal cancer risk. Furthermore, in patients with anal and small intestinal cancer, the observed number of cancers was very small, leading to imprecise estimates.

In conclusion, our observed increased risk of all gastrointestinal cancers within the first year after thyroid disease diagnosis is likely attributable to reverse causation or detection bias. There does not seem to be a causal association between thyroid disease and long-term risk of gastrointestinal cancer.
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[^1]: COPD, chronic obstructive pulmonary disease; GI, gastrointestinal; HIV, human immunodeficiency virus; IBD, inflammatory bowel disease.

[^2]: COPD, chronic obstructive pulmonary disease; GI, gastrointestinal; HIV, human immunodeficiency virus; IBD, inflammatory bowel disease.

[^3]: E, expected events; O, observed events; SIR, standardized incidence ratio.

[^4]: E, expected events; O, observed events; SIR, standardized incidence ratio.
